Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMOI00X)

Drug Name

Ozuriftamab vedotin Drug Info

Synonyms

BA3021

Indication

Disease Entry	ICD 11	Status	REF
Head-neck squamous cell carcinoma	2D60.0	Phase 2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Neurotrophic tyrosine kinase ROR2 (ROR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CCT301-59 (targeting ROR2)	DM0F9CD	Renal cell carcinoma	2C90	Phase 1/2	[3]
CCT301-38 (targeting ROR2)	DM2B1V0	Renal cell carcinoma	2C90	Phase 1/2	[3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Neurotrophic tyrosine kinase ROR2 (ROR2)	TTUDPCI	ROR2_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT05271604) A Phase 2 Open-Label Study of Ozuriftamab Vedotin (BA3021) in PD-1/L1 Failure Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. U.S.National Institutes of Health.
2	Clinical pipeline report, company report or official report of BioAtla
3	ClinicalTrials.gov (NCT03393936) Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma